Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma

• Published in: European journal of drug metabolism and pharmacokinetics Vol. 46; no. 4; pp. 487 - 504
• Main Authors: Bartels, Christian, Jain, Monish, Yu, Jing, Tillmann, Hanns-Christian, Vaidya, Soniya
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.07.2021
• Subjects: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - pharmacokinetics; Asthma - drug therapy; Biomedical and Life Sciences; Biomedicine; Child; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycopyrrolate - administration & dosage; Glycopyrrolate - analogs & derivatives; Glycopyrrolate - pharmacokinetics; Human Physiology; Humans; Indans - administration & dosage; Indans - pharmacokinetics; Male; Medical Biochemistry; Middle Aged; Models, Biological; Mometasone Furoate - administration & dosage; Mometasone Furoate - pharmacokinetics; Nebulizers and Vaporizers; Original; Original Research Article; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacy; Pulmonary Disease, Chronic Obstructive - drug therapy; Quinolones - administration & dosage; Quinolones - pharmacokinetics; Randomized Controlled Trials as Topic; Young Adult
• ISSN: 0378-7966; 2107-0180; 2107-0180
• DOI: 10.1007/s13318-021-00689-x

Background and Objective Clinical evidence suggests no clinically relevant pharmacokinetic interactions between indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF). A population pharmacokinetic (popPK) analysis was conducted to identify structural models describing systemic pharmacok...